Metastatic Pancreatic Cancer

Publication Date: August 5, 2020

Key Points

Key Points

  • There will be an estimated 57,600 new cases and 47,050 deaths as a result of pancreatic cancer in the United States in 2020. There were an estimated 460,000 new cases worldwide in 2018.
  • A diagnosis of pancreatic ductal adenocarcinoma is associated with poor prognosis due to early micrometastatic spread.
  • The 5-year survival rate for metastatic pancreatic cancer is approximately 2.9%.
  • This 2020 update of the 2018 recommendations was triggered by:
    • New evidence for PARP inhibitor olaparib as an option for maintenance therapy after first-line treatment and
    • New studies of tissue agnostic agents that target fusions of the neurotrophin tyrosine receptor kinase (NTRK) 1/2/3 genes.

Diagnosis

...gnosis...

...al Assessment...

...puterized tomography (CT) scan of the chest, abdom...

...baseline performance status (PS), sy...

...goals of care (to include a discussion of a...

...ry collaboration to formulate treat...

...ng for actionable genomic alterations is recom...

...tient with pancreatic cancer should be offered in...


Treatment

...eatment...

...-Line Treatment...

...RINOX (leucovorin, fluorouracil, irinotecan,...

...ne plus NAB-paclitaxel is recommended f...

...one is recommended for patients who have...

...with an ECOG PS 3 or with poorly controlled com...


...t Options Following First-Line Therapy...

...atients with tumors harboring NTRK fusions, treat...

...kpoint inhibitor pembrolizumab is r...

...ients who have a germline BRCA1 or BRCA2 mutat...

...abine plus NAB-paclitaxel may be offered as second...

...luorouracil plus nanoliposomal irinotecan,...

...luorouracil plus oxaliplatin may be consi...

...or fluorouracil can be considered as sec...

...o data are available to recommend third-li...


...alliative Care

...atients with metastatic pancreatic cancer sho...


...ent of Pain and Symptom...

...s with metastatic pancreatic cancer should be off...


Follow-Up

...low-Up

...ow-up/Surveillance

...atients on active cancer-directed ther...

...n the duration of cancer-directed therapy....